This is a summary of the European public assessment report (EPAR) for Alli. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Alli.
Therapeutic Indication
### Therapeutic indication Alli is indicated for weight loss in adults who are overweight (body mass index, BMI, 28 kg/m2) and should be taken in conjunction with a mildly hypocaloric, lower-fat diet.
Therapeutic Area (MeSH)
N/AATC Code
A08AB01
ATC Item
orlistat
Pharmacotherapeutic Group
Antiobesity preparations, excl. diet products
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| orlistat | N/A | 奥利司他 |
EMA Name
Alli (previously Orlistat GSK)
Medicine Name
Alli (previously Orlistat GSK)
Aliases
N/ANo risk management plan link.
